Serum actin-binding proteins as markers of metastasis of larynx and laryngeal pharynx cancer

Poster (download)

151

Video (download)

Kakurina G.V.¹, Kolegova E.S², Staheeva M.N.³, Cheremisina O.V.⁴, Kondakova I.V.⁵, Choynzonov E.L.^6
1Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences Tomsk, Russia, kakurinagv@oncology.tomsk.ru
²Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences Tomsk, Russia, biochem@oncology.tomsk.ru
³Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences Tomsk, Russia, stakheyevam@oncology.tomsk.ru
⁴Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences Tomsk, Russia, onco@tnimc.ru
⁵Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences Tomsk, Russia, biochem@oncology.tomsk.ru
⁶Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences Tomsk, Russia, onco@tnimc.ru

To determine the markers of metastasis, it is important to study the molecular characteristics of tumor progression among patients with Squamous cell carcinoma of the larynx and larynxopharynx (L/L SCC). The aim of the study was to study the relationship between the level of actin binding proteins (ABS) (adenylyl cyclase-associated protein 1 (CAP1), cofilin 1, ezrin, fascin 1 and profilin 1) in the blood serum of patients with L/L SCC with the main clinical and morphological characteristics and to assess the possibility of their use as markers of metastasis. Several serum ABPs (CAP1, profilin1 and fascin 1) have been identified as potential markers of metastasis of L/L SCC. For the presented sample of patients a metastasis prognosis model was obtained. For further conclusions about the clinical value of the proposed metastasis markers, further studies with an expanding sample of patients are needed.